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We investigated the potential of weekly cisplatin and daily oral etoposide followed by oral etoposide maintenance therapy in
patients with platinum-refractory ovarium cancer. One hundred and seven patients were entered on the study, 98 patients
completed the induction therapy consisting of cisplatin at either 50 or 70 mg m
72 weekly for six administrations plus oral
etoposide at a dose of 50 mg daily. Of these 98 patients, 38 had a platinum treatment-free interval of more than 12 months,
32 had an interval between 4 and 12 months, and 28 had progressed during or within 4 months after last platinum therapy.
We assessed response rates and time to progression, and also response duration and survival. Analyses were done on the 98
evaluable patients. All 107 patients were considered evaluable for toxicity. Of the 38 patients with a treatment-free interval of
more than 12 months, 92% responded, with 63% complete responses. The median progression-free survival in these patients
was 14 months, and the median survival was 26 months. Of the 32 patients with an interval of 4–12 months, 91% responded,
with 31% complete responses, a median progression-free interval of 8 and a median overall survival of 16 months. Of the 28
patients with platinum-refractory disease, 46% as yet responded, with 29% complete responses, median progression-free
interval of 5 and an overall survival of 13 months. Haematologic and non-haematologic, particularly renal toxicity and
neurotoxicity, were notably mild. We conclude that this intensive regimen of weekly cisplatin plus daily etoposide is highly
effective and well tolerated in patients with ovarian cancer relapsing after conventional platinum-based combination
chemotherapy, including patients who have progressed during or within 4 months after platinum treatment.
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Despite the established role of platinum-based combination
chemotherapy in the treatment of ovarian cancer, resulting in
prolonged disease-free survival even in patients with overt meta-
static disease, unfortunately the majority of patients eventually
will relapse (Neijt et al, 1991).
Although reinduction therapy with platinum compounds may
again produce responses, durable survival is rare. Multiple
studies have shown that the time interval between the comple-
tion of ﬁrst-line chemotherapy and the relapse is the most
important prognostic factor in the likelihood of responding
to second-line therapy (Seltzer et al, 1985; Gershenson et al,
1989; Kavanagh and Nicaise, 1989; Markman et al, 1991; van
der Burg et al, 1991; Kjorstad et al, 1992; Berek et al,
1998). This impact accounts not only for the successful rein-
duction rate to platinum but also for the response rate to
other active agents, including the taxanes, topotecan, gemcita-
bine and anthracyclins (de Wit et al, 1994; Eisenhauer et al,
1994; Lund et al, 1994; Kavanagh et al, 1996; Muggia et al,
1997; ten Bokkel Huinink et al, 1997; Rose et al, 1998). In
patients who relapse within 4 months following ﬁrst-line ther-
apy, usually deﬁned as platinum-refractory disease, the response
rate to any conventional platinum regimen as well as to other
compounds is less than 15%. In patients who relapse between
4 and 12 months following therapy, deﬁned as intermediate
platinum-sensitive disease, responses are obtained in 20–30%
of patients, and are usually of brief duration. Only if relapses
occur more than 12 months after ﬁrst line treatment, 50% of
the patients will again beneﬁt from platinum-containing rein-
duction chemotherapy, which can be considered standard of
care.
In view of the observed dose–response relationship for plati-
num compounds in in-vitro ovarian cancer models, dose-
intensive therapy has been investigated in phase II studies
(Ozols et al, 1987). An alternative strategy to increase the dose
of cisplatin administered over a given period of time, is to
reduce the interval between cycles. We have previously shown
that by inducing a chloro-uresis through dissolving cisplatin
in 3% hypertonic saline, cisplatin at a dose of 70 mg m
72
weekly can be safely administered in platinum-naive patients
with solid tumours (Planting et al, 1993). In view of the
observed synergy between cisplatin and etoposide (Mabel,
1979; Chambers et al, 1987) and the activity of prolonged oral
administration of etoposide, (de Wit et al, 1994; Rose et al,
1998) we subsequently investigated combined weekly cisplatin
with daily etoposide (Planting et al, 1995). We presently report
on a phase II study with this new modality of weekly cisplatin
and daily oral etoposide in patients failing conventional plati-
num-based combination chemotherapy.
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Patients
Eligibility required histologically conﬁrmed epithelial ovarian
cancer (Brenner tumours and borderline tumours were
excluded), progressive disease or relapse after at least one plati-
num combination regimen, WHO performance status 0–2,
bidimensional target lesion measurable disease by radiographic,
gynaecological or physical examination. Pretreatment laboratory
requirements included WBC 53.0610
9 l
71, platelets
5100610
9 l
71, serum bilirubin 425 mmol l
71, serum creatinine
4120 mmol l
71 and/or a creatinine clearance 560 ml min
71.
Exclusion criteria were peripheral neuropathy from previous ther-
apy Common Toxicity Criteria (CTC) 5grade 2, or bowel
obstruction. At the initiation of the study only the platinum-
sensitive patients (recurrence 412 months after last platinum
chemotherapy) were eligible. When this regimen of weekly cispla-
tin and daily etoposide showed to be both effective and feasible,
the study protocol was amended to include all patients with
progression during or within 12 months after platinum
chemotherapy. The protocol was approved by the Institutional
Ethics Board. All patients gave written informed consent.
Treatment
The treatment regimen consisted of 6 weekly i.v. cisplatin infusions
on day 1, 8, 15 and day 29, 36, 43, combined with daily oral etopo-
side 50 mg on days 1–15 and days 29–43. The cisplatin dose was
50 mg m
72 in the platinum-sensitive patients, and later during the
conduct of the study 70 mg m
72 in the intermediate-sensitive and
-refractory patients. Patients with a response or stable disease after
the sixth cisplatin administration continued treatment with oral
etoposide 50 mg m
72 per day for 21 days, every 4 weeks, for 6–
9 cycles.
Cisplatin was dissolved in 250 ml NaCl 3% and administered
over 3 h. The cisplatin infusion started after prehydration with
1000 ml dextrose-saline with 20 mmol KCl and 2 g MgSO4. After
the cisplatin infusion the patients received posthydration consisting
of 2 liters dextrose-saline with 40 mmol KCl and 4 g MgSO4 given
over 8 h. All patients received ondansetron 8 mg and dexametha-
sone 10 mg i.v. 30 min before the start of cisplatin.
Dose reductions
Weekly cisplatin and daily etoposide If on day 8 or day 36
WBC was 52.5610
9 l
71 and/or platelets 575610
9 l
71, treat-
ment was postponed 1 week until recovery. If on day 15 or 43
WBC was 51.5610
9 l
71 and/or platelets 550610
9 l
71 the
cisplatin infusion was omitted. If on day 29 WBC was
53.0610
9 l
71 and/or platelets 5100610
9 l
71, the treatment
was postponed 1 week until recovery. Cisplatin administration
was ceased in case the creatinine clearance fell below 45 ml min
71
or in case of neurotoxicity grade 53.
Etoposide monotherapy
If WBC was 53.0610
9 l
71 and/or platelets 5100610
9 l
71 on
day 1, the treatment was postponed 1 week until recovery. If on
day 8 or day 15 WBC was 52.0610
9 l
71 and/or platelets
550610
9 l
71, the cycle was discontinued.
Treatment monitoring
During treatment, weekly blood counts, serum electrolytes, renal
and liver function tests were performed. Response to treatment
was assessed by physical and gynaecological examination, vaginal
ultrasound and CT scan on day 56 and every 3 months thereafter.
In case of discrepancy in response assessment, response was deter-
mined by the study team. The worst response was then taken into
account for the analysis. A senior staff member of the Institute who
was not involved in the conduct of the study reviewed all
responses. Responses were determined according to World Health
Organization (WHO) criteria (WHO, 1979).
Safety parameters
Quantitative haematologic and non-haematologic toxicities were
assessed according to the National Cancer Institute (NCI) common
toxicity criteria (CTC). For the assessment of toxicity, the patients
were grouped according to the cisplatin dose of 50 and 70 mg m
72
weekly, respectively.
Statistical methods
Main endpoints for the analysis were response, response duration,
progression-free survival (PFS), overall survival (OS) and toxicity.
Response duration, PFS and OS were calculated by actuarial meth-
ods. The response duration and PFS was deﬁned as the interval
between the start of treatment and progression. The OS was
deﬁned as the interval between the start of therapy and death or
last follow-up of all evaluable patients, with censoring of the
patients alive at last follow-up. The method of Kaplan and Meier
was used to calculate median survival times and probabilities at
1 and 2 years after start of treatment. The Cox regression model
was used to test for differences in PFS and OS between subgroups
deﬁned by platinum sensitivity, performance status, histology,
tumour size, the presence of ascites, and the number of previous
chemotherapy regimens.
For the response and survival evaluations the patients were
grouped according to the deﬁnition of the recent consensus clas-
siﬁcation (Berek et al, 1998); patients with an interval less than 4
months between progression and the last platinum-based
chemotherapy were deﬁned platinum-refractory, an interval
between 4–12 months was deﬁned intermediate-sensitive, and
an interval of more than 12 months was deﬁned platinum-sensi-
tive.
Patients were considered evaluable for response if they had
completed the induction therapy of the weekly administrations of
cisplatin plus daily etoposide. Patients were evaluable for toxicity
if they had received at least one administration of cisplatin.
RESULTS
Patient characteristics
One hundred and seven patients were entered onto the study. One
patient was ineligible since she has no measurable or evaluable
disease. Eight patients were not evaluable for response since they
did not complete the induction therapy. Reasons were patient refu-
sal after 1–3 cycles (5) abdominal aneurysm (1) and myocardial
infarction (1), ileus after one cycle (1). The patient characteristics
of the 98 patients who were eligible and evaluable for response
are presented in Table 1.
The greater majority of patients had been previously treated
with one or two regimens of cisplatin plus cyclophosphamide or
carboplatin plus cyclophosphamide between 1994 and 1997 when
platinum-paclitaxel combination chemotherapy had not yet
become standard induction therapy. The mean cumulative cisplatin
dose per m
2 at enrollment of the study was 306 mg (s.d. 264). The
mean cumulative carboplatin dose per m
2 at enrollment was
1328 mg (s.d. 1527). A total of eight patients had previously been
treated with paclitaxel containing chemotherapy, and six patients
had been treated with topotecan.
The median duration of follow-up was 13 months for platinum-
refractory patients (= median survival), 16 months for inter-
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platinum-sensitive patients.
Toxicity of weekly cisplatin and daily etoposide
All 107 patients were considered evaluable for toxicity. The haema-
tologic and non-haematologic toxicity by dose of cisplatin is listed
in Table 2. Forty patients received a total of 263 administrations at
a cisplatin dose of 50 mg m
72, and 67 patients received 358
administrations at a dose of 70 mg m
72. Myelotoxicity was accep-
table with no more than one case of neutropenic fever. A number
of patients, ﬁve on 50 mg m
72, and 17 on 70 mg m
72, had grade
4 trombocytopenia, but there were no haemorrhages. As a result of
the blood cell counts on days 29, and nadir counts on days 36 and
43, in 40% of the patients treatment was postponed once by 1
week, and in 10% twice.
Non-haematologic toxicity was notably mild. At the start of
study treatment, 31 patients had grade 1 and four patients had
grade 2 neurotoxicity resulting from the prior platinum therapy.
After completion of the weekly induction therapy an additional
21 patients had acute grade 1 neurotoxicity and one patient had
grade 2 neurotoxicity, whereas neurotoxicity had not clinically
signiﬁcantly worsened in the patients with preexisting neuropathy.
No neuromotor toxicity was observed.
Late neurotoxicity, evaluated 6 months after the completion of
the weekly cisplatin cycles accounted for a total of 22 patients
with grade 1 symptoms and six patients with grade 2 symptoms.
Renal toxicity was mild. Renal toxicity grade 1 and 2 was
observed in 4% of the patients receiving cisplatin at the dose
of 70%. The highest measured creatinine value was 165 mmol.
After 6 months follow-up one patient still had grade 2 nephro-
toxicity.
Toxicity of etoposide monotherapy
Of the 98 patients who completed the weekly cisplatin and oral
etoposide treatment, 90 patients continued with oral etoposide;
20 patients in the platinum-refractory group continued for a
median of three cycles (range, 1–9 cycles), 32 patients in the inter-
mediate-sensitive group for a median of three cycles (range, 1–9
cycles), and 38 platinum-sensitive patients for a median of six
cycles (range, 1–9 cycles).
Haematologic toxicity during the maintenance therapy with
daily oral etoposide rarely resulted in grade 4 toxicity (2%).
There was one fatal case of neutropenic sepsis. Non-haematologic
toxicity of etoposide was generally mild, with fatigue, mostly
related to treatment related anaemia and grade 1 or 2 stomatitis
in 4%.
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Table 1 Patient characteristics according to progression free interval (PFI) since
last platinum therapy
Refractory Intermediate Sensitive
PFI54 PFI 4–12 PFI412
Category months months months
Eligible patients 28 32 38
Age
Median 55 58 60
Range 37–74 38–78 34–76
Performance status
WHO 0 10 13 22
WHO 1 13 17 13
WHO 2 5 2 3
Histology
Serous 6 9 10
Mucinous 3 1 3
Endometrioid 4 4 4
Clear cell 1 2 1
Adenocarcinoma 14 16 20
Tumour grade
11 1 4
29 7 9
31 5 2 2 2 4
Unclassiﬁed 3 2 1
Tumour size
45 cm 7 11 17
5–10cm 15 15 12
410 cm 6 6 8
Unclassiﬁed 0 0 1
Number of prior platinum regimens
One 17 23 33
Two 9 8 5
Three 2 1 0
Platinum free interval (months):
Median 0.7 7 25
Previous paclitaxel containing therapy 5 3 0
Previous topotecan containing therapy 4 2 0
Median cumulative dose m
72 of cisplatin 225 0 450
Range 0–675 0–600 0–900
Median cumulative dose m
72 of carboplatin 1800 2100 0
Range 0–6300 0–7700 0–3500
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The planned dose intensity of six administrations of cisplatin,
calculated over a treatment period of 8 weeks, was 37.5 mg m
72
week
71 for the 50 mg m
72 patients and 52.5 mg m
72 week
71
for the 70 mg m
72 patients. The achieved median dose intensity
was 32 mg m
72 week
71 (range 21–38 mg m
72 week
71) and
45 mg m
72 week
71 (range 21–53 mg m
72 week
71), respectively.
The median dose-intensity achieved with oral etoposide mainte-
nance therapy was 41 mg m
72 week
71 (range 21–51 mg m
72
week
71).
Response and survival
At the time of completion of the weekly cisplatin and daily etopo-
side there were four complete responses (CR) and seven partial
responses (PR) in the 28 platinum-refractory patients (39%), three
CR and 26 PR in the 32 intermediate-sensitive patients (91%), and
ﬁve CR and 24 PR in the 38 platinum-sensitive patients (76%). Of
the 38 platinum-sensitive patients, 14 underwent interval surgery,
which conﬁrmed four CR, one clinical CR patient had minimal
residual disease, and in four patients with a PR residual tumour
was debulked to less than 1 cm.
During and at the time of completion of daily etoposide main-
tenance therapy in responding and stable disease (SD) patients,
several PR’s converted into CR and SD into PR. The overall
response to the protocol treatment is shown in Table 3. The overall
response rate to weekly cisplatin plus daily etoposide and contin-
ued treatment with daily oral etoposide was as high as 92% in
platinum-sensitive patients, 91% in intermediate-sensitive patients,
and 46% in refractory patients.
Within the group of patients with platinum-sensitive tumours
who had a 92% overall response rate, 24 of 38 (63%) of patients
obtained a CR. The median response duration in this group was
14 months, the median PFS was 14 months and the median OS
was 26 months. Although the 32 patients in the intermediate group
also had a high overall response rate of 91%, the CR rate was
lower, 10 of 32 (31%), compared with that observed in the sensi-
tive group. Also, the median response duration of 9 months, the
median PFS of 8 months and the median OS of 16 months were
less than were observed in the sensitive group. Of the 28 patients
who were considered cisplatin-refractory, 13 (46%) still responsed
to weekly cisplatin plus daily etoposide reinduction therapy and
daily oral etoposide maintenance therapy, eight of whom (29%)
obtained a CR. The median response duration in the refractory
patient group was 7 months, the median PFS was 5 months, and
the median OS was 13 months. Response durations, PFS and OS
in the three groups are shown in Table 3. Figures 1 and 2 show
the curves for PFS and OS in the three groups.
Prognostic factors
The median PFS and OS in patients with a WHO performance of
zero was 12 and 23 months, respectively, vs 7 and 13 months,
respectively, in patients with WHO performance status 1–2. In
patients with tumour lesions less than 5 cm the median PFS and
OS was 14 and 25 months, respectively, vs 6 and 13 months,
respectively, in patients with larger lesions.
In the univariate analysis, progression-free interval (PFI) since
the last platinum-based chemotherapy, performance status and
tumour size were signiﬁcant prognostic factors both for PFS and
OS (Table 4). In the Cox regression analysis, PFI since the last
platinum-based chemotherapy, performance status and tumour size
were statistically signiﬁcant prognostic factors for both the OS and
PFS, except for tumour size, which did not reach statistical signiﬁ-
cance for PFS (Table 4).
DISCUSSION
In patients with ovarian cancer who relapse following platinum-
based combination chemotherapy, the use of reinduction therapy,
again consisting of a platinum-based regimen is considered effec-
tive only if the interval between the completion of platinum
therapy and recurrence is at least 12 months. In patients who
relapse within 12 months following the completion of therapy,
reinduction platinum-based therapy is generally considered not
appropriate, and alternative options including the use of new active
agents have been widely adopted as standard of care. The key refer-
ence to substantiate that effective reinduction therapy with
platinum is restricted to patients with PFIs of more than 12
months is the study reported by Markman et al (1991). In that
study the response rate to salvage platinum chemotherapy was
50% in patients with an interval of 512 months following comple-
tion of prior therapy, whereas patients with briefer intervals
responded in less than 30% of cases. In the subgroup of patients
who had relapsed during or within 4 months after completion of
therapy, further treatment with platinum was found ineffective.
Consequently, based upon the treatment-free interval patients have
been classiﬁed as potentially platinum-sensitive (412 months
interval), intermediate-sensitive (4–12 months), and -refractory
(relapsing during or within 4 months after platinum therapy). In
recent consensus classiﬁcations these categories still exist and are
widely used to determine appropriate therapy for individual
patients (Berek et al, 1998). Of note, these results, as well as those
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Table 2 Toxicities during cisplatin etoposide (worst toxicity per patient)
Cisplatin 50 mg m
72 Cisplatin 70 mg m
72
CTC grade CTC grade
0123401234
Haematologic toxicity (%)
Hb 0 30 67 0 2 0 6 85 4 1
P L T 3 73 0 21 71 21 62 21 81 52 5
WBC 5 12 37 40 5 3 6 30 42 16
Non-haematologic toxicity (%)
Nausea 7 57 32 2 0 3 42 52 3 0
Vomiting 22 27 45 5 0 10 25 52 10 1
Stomatitis 80 17 2 0 0 87 9 4 0 0
Alopecia 15 25 60 0 0 15 30 55 0 0
Fatigue 50 45 5 0 0 40 33 27 0 0
Neurohearing 70 10 20 0 0 61 6 28 4 0
Neurosensory 40 55 5 0 0 45 45 10 0 0
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platinum-based therapy with either cisplatin or carboplatin admi-
nistered every 3 or 4 weeks.
Thus far, there have been limited data to support the use of
weekly cisplatin salvage therapy in patients with ovarian cancer
relapsing after conventional platinum-based therapy (Bolis et al,
1994).
We previously reported several studies investigating the feasibil-
ity and the efﬁcacy of weekly cisplatin plus daily etoposide in
patients with solid tumours (Planting et al, 1995). In view of the
favourable results obtained in these studies, we initiated the current
phase II study in patients with ovarian cancer relapsing after plati-
num-based chemotherapy. We began our study in patients who
had a treatment-free interval of more than 12 months, who
received cisplatin at a dose of 50 mg m
72 weekly plus daily etopo-
side. With increasing experience we amended the protocol to also
include patients with treatment intervals less than 12 months, who
were scheduled to receive cisplatin at a dose of 70 mg m
72 weekly
plus daily etoposide. Despite prior treatment with platinum
compounds, with 22% of the patients having received two and
3% of the patients having received even three prior platinum
containing regimens, we found that non-haematologic toxicity,
particularly neurotoxicity and renal toxicity was notably mild.
Haematologic toxicity resulted in several treatment postpone-
ments and dose reductions, but the median dose intensity of
cisplatin achieved in patients scheduled to receive 50 mg m
72 days
1, 8, 15 and 29, 36 and 43 (equaling 37.5 mg m
72 week
71) was
32 mg m
72 week
71, and in patients scheduled to receive
70 mg m
72 (calculated dose per week 52.5 mg m
72) it was
45 mg m
72. Haematologic complications were few, with no more
than one episode of neutropenic fever.
We found this regimen of weekly cisplatin plus daily etoposide
highly effective. Of the 38 cisplatin-sensitive patients 92%
responded, with 63% complete responses, a response duration
and PFS exceeding 1 year and OS exceeding 2 years. We also
observed considerable effectiveness in patients considered only
intermediately platinum-sensitive. In this group of 32 patients we
obtained 91% responses, including 31% CR, a response duration
of 9 months, PFS of 8 months, and an OS of 16 months. Even
in the group of 28 patients who were considered platinum-refrac-
tory, with a median time since last platinum treatment of only 0.7
months (range 0–3.7 months), we still obtained 46% responses,
including 29% CR, a response duration of 7 months, PFS of 5
months, and OS of 13 months. These results compare strikingly
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Table 3 Best response, progression-free survival and overall survival
Refractory Intermediate Sensitive
Category PFI 54 months PFI 4–12 months PFI 412 months
Number of patients 28 32 38
Overall response
Response rate 13 (46%) 29 (91%) 35 (92%)
Complete response 8 (29%) 10 (31%) 24* (63%)
Partial response 5 (18%) 19 (60%) 11 (29%)
Stable disease 9 (32%) 2 (6%) 3 (8%)
Progression 6 (21%) 1 (3%) 0
Response duration
Median 7 months 9 months 14 months
1 year 31% 21% 66%
2 years 15% 0% 11%
Progression free survival
Median 5 months 8 months 14 months
1 year 14% 19% 63%
2 years 7% 0% 13%
Survival
Median 13 months 16 months 26 months
1 year 54% 53% 92%
2 years 21% 24% 63%
*Including four patients who underwent interval debulking surgery between weekly cisplatin plus oral
etoposide and etoposide maintenance therapy.
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Figure 1 PFS according to platinum sensitivity.
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Figure 2 Survival according to platinum sensitivity.
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and others (Seltzer et al, 1985; Gershenson et al, 1989; Kavanagh
and Nicaise, 1989; van der Burg et al, 1991; Kjorstad et al,
1992), using reinduction therapy with 3- or 4-weekly intervals.
Of note, cisplatin at a dose of 70 mg m
72 weekly six times in a
period of 8 weeks, compared with the standard dose of
75 mg m
72 every 3 weeks results in a 2.1-fold higher schedule-
intensity.
The criterion of treatment-free interval since last platinum ther-
apy is also indicative for the response rate to other agents. The
newly adopted agents such as paclitaxel and docetaxel, topotecan,
caelyx and gemcitabine, although effective in patients with treat-
ment-free intervals of more than 12 months, are infrequently
producing responses in patients who are considered cisplatin-
refractory. Response rates with these new agents in this subgroup
of patients are consistently 15% or less, and even in patients
considered intermediate-sensitive to platinum retreatment, these
new compounds in monotherapy give response rates of no more
than 20–30%, with a median PFS of 3–5 months at best (Eisen-
hauer et al, 1994; Kohn et al, 1994; Lund et al, 1994; Kavanagh et
al, 1996; Muggia et al, 1997; ten Bokkel Huinink et al, 1997; Trope ￿
et al, 1998; Gordon et al, 2000).
The greater majority of our patients in this study had received
their initial chemotherapy in the era that the platinum-paclitaxel
combination had not yet been introduced. As a consequence, the
majority of our patients had received one or two regimens consist-
ing of cisplatin plus cyclophosphamide every 3 weeks, or
carboplatin plus cyclophosphamide every 3 or 4 weeks. As the
purpose of our study was to investigate the potential of sche-
dule-intensive cisplatin in patients who had previously been
treated with conventionally scheduled platinum therapy we do
not believe that the main clinical ﬁnding reported in this study
with weekly cisplatin plus etoposide would be different if paclitaxel
had been substituted for cyclophosphamide in the ﬁrst line regi-
men.
In view of these results, we believe that unless toxicity from
previous therapy prohibits the use of cisplatin, all patients with
ovarian cancer irrespective of the platinum-free interval should
be considered for a rechallenge with therapy containing weekly
cisplatin. In this study we report on weekly cisplatin plus daily
etoposide. Weekly cisplatin can be combined with other agents that
are active in ovarian cancer, and we are currently investigating the
potential of the combination of weekly cisplatin plus weekly pacli-
taxel (van der Burg et al, 1998).
We conclude that schedule-intensive treatment with weekly
cisplatin plus daily oral etoposide is highly effective in patients with
ovarian cancer relapsing after conventional platinum-based combi-
nation chemotherapy, including patients who have progressed
during or relapsed within 4 months after the completion of treat-
ment. The optimal use of schedule intensive therapy incorporating
new active agents, such as paclitaxel, is currently being investigated.
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